Crovalimab

Starting January 1, 2025, Independence Blue Cross updates specialty drugs requiring precertification for certain plans. Includes FDA-approved drugs like Ahzantive, Bkemv, and pending approval drugs. Updates also reflect brand name changes for previously added drugs.

Genentech presents key studies on Polivy, Lunsumio, Columvi, Venclexta, Hemlibra, and PiaSky at medical conferences, highlighting efficacy and safety profiles of these medicines in treating various blood cancers and hemophilia A.

Roche reports 6% Group sales growth at constant exchange rates, driven by high demand for medicines and diagnostics. Pharmaceuticals Division sales rose 7%, with strong growth in base business, led by Vabysmo, Phesgo, and Ocrevus. Diagnostics Division sales increased 5%, with base business growing 8%. Key developments include US and EU approvals for new treatments, positive phase III data, and acquisitions to strengthen pipelines. Outlook for 2024 is confirmed.

Q3 2024 saw approval of 5 novel antibody drugs, increased ADC research, and $3B in collaborations. Investment in antibodies continues, with startups raising up to $370M. Promising antibodies for Q4 include treatments for genetic disorders and cancers.

Roche's phase III REGENCY study showed Gazyva/Gazyvaro plus standard therapy achieved higher complete renal response rates in active lupus nephritis compared to standard therapy alone, with no new safety signals. This could be a significant advancement for patients, potentially preventing end-stage kidney disease.

Genentech announced positive Phase III REGENCY study results for Gazyva, showing it plus standard therapy achieved a higher complete renal response rate in active lupus nephritis patients compared to standard therapy alone, with no new safety signals.

Genentech announced positive Phase III REGENCY study results for Gazyva® in active lupus nephritis, showing higher complete renal response rates with Gazyva plus standard therapy compared to standard therapy alone. Gazyva targets disease-causing B cells to prevent progression to end-stage kidney disease.